The cornerstones of Evotec’s in vitro pharmacology function are disease and target biology expertise coupled with state-of-the-art technology platforms. A large team of scientists with extensive industrial experience supports the in vitro pharmacological characterisation of compounds as part of hit expansion, lead finding and lead optimisation projects. The in vitro pharmacology team routinely generates project-relevant high-quality data in short turnaround times. In addition, we support in vivo studies with PD read-outs and engage in early translational biology research. In addition to its extensive capabilities in mammalian biological systems, Evotec has in-depth in vitro microbiology expertise spanning a broad range of pathogens from bacteria to fungi and viruses.
The Company’s offering includes:
- Development of biochemical and functional assays
- Secondary and tertiary characterisation of screening hits
- Compound profiling as part of hit-to-lead and lead optimisation programmes:
- Design and implementation of target-relevant assays (screening cascades)
- Potency and selectivity testing
- Mode-of-action studies (e.g. competitive versus allosteric mechanisms, reversibility, use-dependent mechanisms for ion channel modulators)
- Translational cellular assays to bridge the gap between in vitro and in vivo studies: Testing of compound potency and mechanism using disease-relevant primary cells from rodents, primates or humans
- Translational biomarkers: Building assays in the discovery phase that allow measuring target engagement in patients and thus de-risking of clinical projects
In more than 15 years of compound profiling at Evotec, more than 400 assays have been developed and executed. Such activities are part of Evotec’s integrated lead finding and optimisation projects but are also frequently used to support medicinal chemistry projects that are executed in labs of Evotec’s customers.
For more detailed information, please click on this link or contact us at firstname.lastname@example.org.